Jenoptik (JNPKF) AI Stock Analysis

Jenoptik

(Other OTC:JNPKF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Backlog and GuidanceThe sharp increase in orders, 1.4 book-to-bill and substantial backlog provide forward revenue visibility across the business. Converting 60%–65% of backlog to sales, alongside upgraded guidance, supports durable execution potential over the next several quarters.

Negative Factors

MPS Automotive WeaknessContinued European automotive weakness can suppress demand for metrology and production solutions, limiting group growth and keeping MPS below acceptable profitability. The unit's loss-making status also creates a drag on consolidated margins until end-market conditions improve.

Jenoptik (JNPKF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $2.25B
Dividend Yield: 1.06%
Average Volume (3M): 6,337
Price to Earnings (P/E): 25.8
Beta (1Y): 0.96
Revenue Growth: 4.98%
EPS Growth: 20.81%
Country: US
Employees: 3,975
Sector: General
Sector Strength: 55
Industry: Hardware, Equipment & Parts

Jenoptik Business Overview & Revenue Model

Company Description

Jenoptik AG provides advanced photonic solutions and smart mobility solutions in Germany and internationally. The company operates through Semiconductor & Advanced Manufacturing, Biophotonics, Metrology & Production Solutions, and Smart Mobility Solu...

Jenoptik Earnings Call Summary

Earnings Call Date:Aug 11, 2026(Q2-2026)|% Change Since:-3.57%|Next Earnings Date:Nov 09, 2026

Earnings Call SentimentPositive

The call conveyed a broadly positive operational and financial momentum: very strong order intake (+50%+), a substantial backlog (~EUR 825m) and marked margin expansion (EBITDA +25%, +400 bps) underpin an upgraded confidence level with guidance moved to the upper half of ranges (revenue growth 5–9%, EBITDA margin 20–21%). Offsetting factors include modest H1 revenue growth (1%), working capital pressure reducing operating cash flow, uneven performance across segments (MPS softness, biophotonics revenue decline despite higher orders), and order volatility/pull‑forward risk. On balance, the constructive operational execution and margin improvement, together with a stronger backlog and upgraded guidance, outweigh the near‑term cash and segment challenges.

Positive Updates

Very Strong Order Intake

Group order intake rose by more than 50% year‑on‑year in H1 2026, driven by OEM (semi) and biophotonics demand; H1 book‑to‑bill improved to 1.4 and order backlog grew to around EUR 825 million.

Negative Updates

Biophotonics Revenue Decline Despite Order Strength

Although biophotonics order intake rose ~45% YoY, H1 revenues in biophotonics were down by almost 5% year‑on‑year due to base effects (strong dental comparatives) and revenue mix; company cautioned that order volatility in this unit will remain high.

Company Guidance

Guidance was tightened upward: on the basis of year‑to‑date performance Jenoptik now expects full‑year revenue growth in the upper half of its single‑digit range, i.e., roughly +5% to +9%, and an EBITDA margin in the upper half of the prior 19%–21% range (now guided to ~20%–21%); CapEx guidance is unchanged (expected slightly below last year). This update sits alongside strong H1 metrics — group order intake +>50% YoY, H1 book‑to‑bill 1.4, order backlog ~EUR 825m (with management expecting to convert ~60%–65% of backlog to sales), H1 revenues modestly +1% (ex‑FX ~+3%), semi revenues ~+10%, biophotonics ~‑5%, SMS ~+11%, group EBITDA ~EUR 99m (+>25% YoY) with EBITDA margin up ~400 bps, semi EBITDA margin ~32%, biophotonics ~22%, EBIT margin 12.3% and EPS €0.69 (vs €0.42). Management cautioned that some H1 orders were pulled forward and that the very strong H1 order dynamics may not fully continue in H2, while noting working capital is up and expected to trend slightly above 2025 levels and free cash flow was slightly improved year‑on‑year.

Jenoptik Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JNPKF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:AFX	73Outperform	EUR 3.13B	20.86	5.52%	1.58%	-0.06%	-38.81%
DE:BSL	69Neutral	EUR 703.05M	24.35	20.29%	0.49%	31.07%	―
DE:SMHN	67Neutral	EUR 973.94M	35.31	8.73%	0.08%	-15.45%	-51.36%
DE:SIS	60Neutral	EUR 563.45M	39.42	18.80%	0.87%	-18.11%	―
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:LPK	46Neutral	EUR 251.09M	-11.18	-33.16%	―	-26.24%	-2180.10%

* General Sector Average

Performance Comparison

JNPKF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JNPKF	Jenoptik AG	43.40	21.75	100.47%
DE:BSL	Basler AG	22.65	6.61	41.24%
DE:AFX	Carl Zeiss Meditec	34.84	-7.02	-16.77%
DE:SIS	First Sensor	54.00	-2.52	-4.46%
DE:LPK	LPKF Laser & Electronics	10.40	4.39	73.04%
DE:SMHN	Suss Microtec Se	51.20	24.55	92.13%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Jenoptik AI Stock Analysis